Insulinoma Management

Introduction to Insulinoma Treatment

The National Comprehensive Cancer Network recommends that virtually all insulinomas should be surgically resected regardless of size because of the metabolic complications from hypoglycemia, with a 90% cure rate for localized disease 1, 2

The American College of Endocrinology suggests dietary management with frequent small meals as the initial strategy to maintain euglycemia 2, 3
Diazoxide is the first-line pharmacological therapy for managing hyperinsulinemic hypoglycemia, as it directly inhibits insulin secretion, according to the Endocrine Society 2, 3
Everolimus can be considered as an alternative for preoperative stabilization when diazoxide is ineffective or contraindicated, as recommended by the European Society of Endocrinology 2, 3
Octreotide and lanreotide should be avoided or used with extreme caution in insulinoma patients because they suppress counterregulatory hormones, which can precipitously worsen hypoglycemia, according to the National Comprehensive Cancer Network 4, 2, 3

Enucleation is the primary treatment for peripheral or exophytic insulinomas, as 90% are benign, according to the National Comprehensive Cancer Network 5, 2
Laparoscopic enucleation can be performed for localized solitary tumors in the body and tail of the pancreas, offering shorter hospital stays, as recommended by the Society of Surgical Oncology 5, 2
Distal pancreatectomy with spleen preservation is recommended for smaller tumors not involving splenic vessels that cannot be enucleated, according to the American College of Surgeons 5, 2
Pancreatoduodenectomy (Whipple procedure) is required for deeper, invasive tumors or those with proximity to the main pancreatic duct, as recommended by the National Comprehensive Cancer Network 5, 2

Total parenteral nutrition (TPN) may be necessary in severe cases with profound weight loss, according to the National Comprehensive Cancer Network 4
Subtotal resection (>90% tumor debulking) can effectively palliate symptoms from hormone hypersecretion in selected patients with adequate performance status, as recommended by the National Comprehensive Cancer Network 1

Distal pancreatectomy with enucleation of tumors from the pancreatic head is the recommended approach for MEN1-associated insulinomas, according to the National Comprehensive Cancer Network 1
Resection of dominant tumors (>2-2.5 cm) helps with symptom management and may decrease metastatic risk, as recommended by the National Comprehensive Cancer Network 1

Disease recurrence occurs in 21-42% of patients and can happen after many years, according to the National Comprehensive Cancer Network 5
Follow-up should begin 3-12 months after resection with ongoing surveillance, as recommended by the National Comprehensive Cancer Network 5

Never rely on Octreoscan for insulinoma localization - only 50-60% of insulinomas express somatostatin receptors, compared to 75% for other pancreatic NETs, according to the National Comprehensive Cancer Network 4, 2
Proton pump inhibitors cause spuriously elevated chromogranin A levels, which can complicate diagnosis, as reported by the National Comprehensive Cancer Network 1, 2